AVALO THERAPEUTICS, INC. (AVTX) Return on equity 2016–2025
AVALO THERAPEUTICS, INC. (AVTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-94.2%FY2025 · since FY2016: -7957.2% → -94.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -94.2% | -67.8 pp |
| FY2024 | -26.4% | +405.5 pp |
| FY2023 | -431.9% | — |
| FY2021 | -365.5% | -107.0 pp |
| FY2020 | -258.5% | -182.0 pp |
| FY2019 | -76.6% | +115.0 pp |
| FY2018 | -191.6% | -234.2 pp |
| FY2017 | 42.6% | +7999.8 pp |
| FY2016 | -7957.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Gross marginAVTX Operating incomeAVTX Operating marginAVTX Operating cash flowAVTX Free cash flowAVTX Capital expendituresAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →